Interactive Features

Quiz

Quizartinib for Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3/ITD Mutations

08/03/2023

True or False: The FDA approved quizartinib with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for patients with newly diagnosed acute...

True or False: The FDA approved...

08/03/2023

Oncology

Quiz

Quiz: Treatment Regimen for Older Patients with Newly Diagnosed AML

10/13/2022

True or False: According to a recent phase 2 study, venetoclax added to cladribine and low-dose cytarabine alternating with venetoclax and 5-azacitidine was found to be an effective regimen for older or unfit patients with newly diagnosed AML.

True or False: According to a...

10/13/2022

Oncology

Quiz

Quiz: Post-Transplant Eprenetapopt and Azacitidine Maintenance in TP53-Mutant AML and MDS

10/05/2022

True or False: In a recent phase 2 trial, post-transplant eprenetapopt and azacitidine maintenance demonstrated promising safety and efficacy in TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

True or False: In a recent phase...

10/05/2022

Oncology

Quiz

Quiz: EFS Rates in Patients With IDH1-Mutated AML Treated With Ivosidenib and Azacitidine

09/13/2022

True or False: Treatment with ivosidenib and azacitidine was associated with improved event-free survival vs treatment with placebo and azacitidine in patients with newly diagnosed IDH1-mutated acute myeloid leukemia, according to a phase 3...

True or False: Treatment with...

09/13/2022

Oncology

Quiz

Quiz: Does Midostaurin Offer a Benefit for Patients With AML?

03/14/2022

True or false: Midostaurin has a significant benefit for patients with AML.

True or false: Midostaurin has a...

03/14/2022

Oncology

Test Your Knowledge

Quiz: Does Quizartinib Improve Survival in AML When Added to Nonintensive Chemo?

02/10/2022

True or false: A randomized trial found that quizartinib when added to standard nonintensive chemotherapy improves survival for older patients with AML.

True or false: A randomized...

02/10/2022

Oncology

Test Your Knowledge

Quiz: Does Quizartinib Improve Survival in AML When Added to Nonintensive Chemo?

02/10/2022

True or false: A randomized trial found that quizartinib when added to standard nonintensive chemotherapy improves survival for older patients with AML.

True or false: A randomized...

02/10/2022

Oncology

Test Your Knowledge

Quiz: Which Combo Regimen Improves ORR in Patients With Mutant-IDH2 AML?

01/31/2022

Question: Which of the following combination regimens was well tolerated and significantly improved ORR compared to monotherapy in patients with mutant-IDH2 AML?

Question: Which of the following...

01/31/2022

Oncology

Test Your Knowledge

Quiz: Which Combo Regimen Improves ORR in Patients With Mutant-IDH2 AML?

01/31/2022

Question: Which of the following combination regimens was well tolerated and significantly improved ORR compared to monotherapy in patients with mutant-IDH2 AML?

Question: Which of the following...

01/31/2022

Oncology

Quiz

Quiz: Is This Monotherapy Safe, Well-Tolerated in Newly Diagnosed AML?

01/20/2022

According to data from a phase 2b study, which of the following therapies is generally safe and effective as a first-line therapy for AML patients who are unfit for intensive chemotherapy?

According to data from a phase...

01/20/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology